Explore 3 Stock Ideas & Industry Insights Download Free Report

18889881171
Shopping Cart 0
countryflagUS
Login

Context Therapeutics Inc

Healthcare US CNTX

0.64855USD
0.02(2.96%)

Last update at 2026-06-23T18:50:00Z

Day Range

0.590.70
LowHigh

52 Week Range

0.493.62
LowHigh

Fundamentals

  • Previous Close 0.63
  • Market Cap217.75M
  • Volume2631896
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-39.68638M
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM 0.00000M
  • Diluted EPS TTM-0.38

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -36.12362M -26.72510M -23.96421M -14.83594M -10.45687M
Minority interest - - - - -
Net income -36.12362M -26.72510M -23.96421M -14.29068M -7.43328M
Selling general administrative 7.85M 7.22M 7.29M 7.79M 3.63M
Selling and marketing expenses - - 0.01M - -
Gross profit -0.12466M -0.05270M -0.01204M - -
Reconciled depreciation 0.02M 0.01M 0.01M 0.00927M -
Ebit - -29.92390M -25.07262M -15.38120M -10.52582M
Ebitda -39.70263M -29.91302M -25.06057M -14.37194M -7.31412M
Depreciation and amortization - 0.01M 0.01M 1.01M 3.21M
Non operating income net other - - - - -
Operating income -39.70263M -29.92390M -25.07262M -15.38120M -10.52582M
Other operating expenses 39.70M 29.92M 25.07M 14.88M 7.44M
Interest expense - - - 0.55M 0.06M
Tax provision - - - - -
Interest income 3.38M 3.20M 1.27M 0.55M -
Net interest income 3.38M 3.20M 1.27M 0.55M -0.06424M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense - - -0.00000M -0.54526M -3.02359M
Total revenue 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Total operating expenses 39.70M 29.92M 25.07M 14.88M 7.44M
Cost of revenue 0.12M 0.05M 0.01M - -
Total other income expense net 3.58M 3.20M 1.11M 0.55M 0.07M
Discontinued operations - - - - -
Net income from continuing ops -36.12362M -26.72510M -20.75111M -14.83594M -10.45687M
Net income applicable to common shares - - - - -10.45687M
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 68.49M 98.13M 16.06M 37.97M 51.31M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 2.36M 3.47M 1.60M 2.36M 1.62M
Total liab 8.02M 2.86M 4.19M 3.21M 3.03M
Total stockholder equity 60.47M 95.27M 11.87M 34.76M 48.27M
Deferred long term liab - - - - -
Other current liab 5.38M 1.19M 1.81M 2.22M 1.21M
Common stock 0.09M 0.09M 0.02M 0.02M 0.02M
Capital stock 0.09M 0.09M 0.02M 0.02M 0.02M
Retained earnings -130.90331M -94.77969M -68.05459M -44.09038M -29.25444M
Other liab - - - - -
Good will - - - - -
Other assets - - 0.00000M 0.00000M 0.05M
Cash 66.00M 94.43M 14.45M 35.50M 49.64M
Cash and equivalents - - - - -
Total current liabilities 8.02M 2.75M 4.19M 3.21M 3.03M
Current deferred revenue - - - - -
Net debt -65.88316M -94.21044M -14.44983M -35.44237M -49.63520M
Short term debt 0.11M 0.11M - 0.06M -
Short long term debt - - - - -
Short long term debt total 0.11M 0.22M - 0.06M -
Other stockholder equity 191.29M 189.96M 79.91M 78.83M 77.51M
Property plant equipment - - - - -
Total current assets 68.35M 97.90M 16.05M 37.85M 51.26M
Long term investments - - - - -
Net tangible assets - - - - 48.27M
Short term investments - - - - -
Net receivables - - - - -
Long term debt - - - - -
Inventory - - - - -
Accounts payable 2.53M 1.45M 2.38M 0.94M 1.83M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - - - - -51.30575M
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - - -0.00000M 0.03M 0.05M
Deferred long term asset charges - - - - -
Non current assets total 0.14M 0.23M 0.02M 0.11M 0.05M
Capital lease obligations 0.11M 0.22M 0.00000M 0.06M -
Long term debt total - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - -14.75732M 0.00000M -0.53684M -0.25000M
Change to liabilities - - - - -0.86601M
Total cashflows from investing activities -2.03395M -14.75700M - - -0.25000M
Net borrowings - - - - -
Total cash from financing activities -0.01527M 109.29M 0.00000M -0.10207M 58.39M
Change to operating activities - - - - -1.35884M
Net income -36.12362M -26.72500M -23.96421M -14.83594M -10.45687M
Change in cash -28.43460M 79.98M -21.04762M -14.18814M 49.34M
Begin period cash flow 94.43M 14.45M 35.50M 49.69M 0.34M
End period cash flow 66.00M 94.43M 14.45M 35.50M 49.69M
Total cash from operating activities -26.38538M -14.55600M -21.04762M -13.54923M -8.79949M
Issuance of capital stock 0.00000M 109.29M 0.00000M 0.00000M 58.39M
Depreciation 0.02M 0.01M 0.01M 0.00927M -
Other cashflows from investing activities -2.00000M -14.74968M - - -
Dividends paid - - - - -
Change to inventory - - - - -
Change to account receivables - - - - -
Sale purchase of stock - - - - -
Other cashflows from financing activities -0.01527M 109.29M - -0.41146M 4.98M
Change to netincome - - - - 3.88M
Capital expenditures 0.03M 14.76M 0.00000M 0.54M 0.25M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 6.28M -3.47600M 1.78M -0.27752M -2.22484M
Stock based compensation 1.33M 0.84M 1.08M 0.98M 0.51M
Other non cash items 2.11M 14.79M 0.05M 0.58M 3.37M
Free cash flow -26.41933M -29.31400M -21.04762M -14.08607M -9.04949M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to EBITDA (x)
CNTX
Context Therapeutics Inc		 0.02 2.96% 0.65 - - - 3.43 1.60
NVO
Novo Nordisk A/S		 0.94 2.04% 46.81 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 - -% 45.00 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 2.93 0.63% 469.72 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 5.28 0.86% 617.77 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. The company was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.

Context Therapeutics Inc

2001 Market Street, Philadelphia, PA, United States, 19103

Key Executives

Name Title Year Born
Mr. Martin A. Lehr Co-Founder, Pres, CEO & Director 1984
Ms. Jennifer Minai-Azary CFO & Treasurer 1978
Mr. Alex C. Levit Esq. Chief Legal Officer & Corp. Sec. 1979
Dr. Felix Kim Ph.D. Co-founder & Chair of Scientific Advisory Board NA
Mr. Christopher Beck M.B.A. Sr. VP of Operations NA
Dr. Tarek Sahmoud M.D., Ph.D. Chief Medical Officer 1961
Dr. Evan G. Dick Sr. VP of R&D 1952
Ms. Elizabeth Nemchik CPA Controller NA
Mr. Martin A. Lehr Co-Founder, President, CEO & Director 1984
Mr. Alex C. Levit Esq. Chief Legal Officer & Corporate Secretary 1979

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.